Celyad Oncology SA (CYAD.BR)
EUR 0.47
(0.65%)
EUR 0.47
(0.65%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -6.1 Million EUR | 51.22% |
| 2022 | -12.19 Million EUR | 55.49% |
| 2021 | -27.38 Million EUR | -101.43% |
| 2020 | -13.59 Million EUR | 61.13% |
| 2019 | -34.97 Million EUR | 10.08% |
| 2018 | -38.89 Million EUR | -78.35% |
| 2017 | -21.8 Million EUR | 53.48% |
| 2016 | -46.87 Million EUR | 52.89% |
| 2015 | -99.5 Million EUR | -265.54% |
| 2014 | -27.22 Million EUR | -43.63% |
| 2013 | -18.95 Million EUR | -2518.97% |
| 2012 | -723.63 Thousand EUR | -722.45% |
| 2011 | 116.25 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.07 Million EUR | 0.0% |
| 2023 FY | 10.68 Million EUR | 187.65% |
| 2023 Q4 | -6.1 Million EUR | 0.0% |
| 2023 Q2 | -4.44 Million EUR | 0.0% |
| 2022 Q1 | -18.11 Million EUR | 33.85% |
| 2022 Q4 | 4.44 Million EUR | 0.0% |
| 2022 FY | -12.19 Million EUR | 55.49% |
| 2022 Q2 | -12.22 Million EUR | 32.54% |
| 2021 Q4 | -27.38 Million EUR | -747.6% |
| 2021 Q2 | -8.93 Million EUR | -2.31% |
| 2021 Q1 | -8.73 Million EUR | 35.76% |
| 2021 FY | -27.38 Million EUR | -101.43% |
| 2021 Q3 | -3.23 Million EUR | 63.84% |
| 2020 Q4 | -13.59 Million EUR | 0.0% |
| 2020 Q2 | -22.98 Million EUR | 0.0% |
| 2020 FY | -13.59 Million EUR | 61.13% |
| 2019 Q4 | -34.97 Million EUR | 0.0% |
| 2019 Q2 | -28.73 Million EUR | 0.0% |
| 2019 FY | -34.97 Million EUR | 10.08% |
| 2018 Q4 | -38.89 Million EUR | 0.0% |
| 2018 FY | -38.89 Million EUR | -78.35% |
| 2018 Q2 | -61.08 Million EUR | 0.0% |
| 2017 FY | -21.8 Million EUR | 53.48% |
| 2017 Q2 | -22.25 Million EUR | 0.0% |
| 2017 Q4 | -21.8 Million EUR | 0.0% |
| 2016 FY | -46.87 Million EUR | 52.89% |
| 2016 Q4 | -46.87 Million EUR | 0.0% |
| 2016 Q2 | -51.95 Million EUR | 0.0% |
| 2015 FY | -99.5 Million EUR | -265.54% |
| 2015 Q2 | -115.61 Million EUR | 0.0% |
| 2015 Q4 | -99.5 Million EUR | 0.0% |
| 2014 FY | -27.22 Million EUR | -43.63% |
| 2014 Q2 | -34.75 Million EUR | 0.0% |
| 2014 Q4 | -27.22 Million EUR | 0.0% |
| 2013 Q4 | -18.95 Million EUR | 0.0% |
| 2013 Q2 | -3.77 Million EUR | 0.0% |
| 2013 FY | -18.95 Million EUR | -2518.97% |
| 2012 Q4 | -723.63 Thousand EUR | 0.0% |
| 2012 FY | -723.63 Thousand EUR | -722.45% |
| 2011 FY | 116.25 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nicox S.A. | 13.89 Million EUR | 143.918% |
| European Medical Solutions | 13.93 Million EUR | 143.802% |
| FERMENTALG | 4.19 Million EUR | 245.528% |
| argenx SE | -1.83 Billion EUR | 99.668% |
| BioSenic S.A. | 28.04 Million EUR | 121.759% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 75.701% |
| Onward Medical N.V. | -12.89 Million EUR | 52.676% |
| Oxurion NV | 10.71 Million EUR | 156.975% |
| PHAXIAM Therapeutics S.A. | -275 Thousand EUR | -2118.909% |
| Financière de Tubize SA | 78.62 Million EUR | 107.761% |
| UCB SA | 2.17 Billion EUR | 100.28% |